China Medical System Holdings Limited (“CMS”) through its wholly-owned subsidiary signed an Exclusive Licensing and Registration Agreement with a leading Swiss phyto-pharmaceutical manufacturer Max Zeller Söhne AG (“Zeller”) on 27 August 2013.
According to the agreement, CMS has, in consideration of certain payments payable to Zeller, acquired the exclusive right to import, register, sell, market, promote and distribute three products of Zeller in China (excluding Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan) for a period of 30 years.
The three products are Ze 339, for the treatment of allergic rhinitis; Ze 450, an herbal medicine for the treatment of menopausal discomforts; and Ze 440, a non-hormonal and analgesic-free plant preparation for the treatment of pre-menstrual syndrome and menstrual cycle disorder (Ze 339, Ze 450 and Ze 440 are currently in the process of Trademark registration in China). The import and sale of these products are subject to approval and registration in China.
The agreement with Zeller is the first time CMS obtains in-licensed products for the Direct Academic Oriented Promotion Network with a long-term exclusive product right for the Chinese market. It reflects CMS’s strategy of constantly seeking to strengthen the stability and control of its in-licensed products, and it is beneficial for CMS to formulate its long-term comprehensive development plans and market strategies to promote these three phyto-pharmaceutical products in the Chinese market.